Selective Small Molecule Targeting of Anti-Apoptotic MCL-1
Show simple item record
| dc.contributor.advisor |
Walensky, Loren David
|
|
| dc.contributor.author |
Cohen, Nicole |
|
| dc.date.accessioned |
2012-11-14T13:40:53Z |
|
| dc.date.issued |
2012-11-14 |
|
| dc.date.submitted |
2012 |
|
| dc.identifier.other |
http://dissertations.umi.com/gsas.harvard:10544 |
en |
| dc.identifier.uri |
http://nrs.harvard.edu/urn-3:HUL.InstRepos:9904005 |
|
| dc.description.abstract |
BCL-2 family proteins are key regulators of the mitochondrial apoptotic pathway in health and disease. Anti-apoptotic members such as BCL-2, \(BCL-X_L\), and MCL-1 have been implicated in the initiation, progression, and chemoresistance of human cancer. Small molecules and peptides have successfully targeted the anti-apoptotic BCL-2/\(BCL-X_L\) groove that binds and sequesters pro-apoptotic BH3 death helices. Such compounds induce tumor cell apoptosis and are being advanced in clinical trials as promising next-generation cancer therapeutics. Notably, selective antagonists such as ABT-737 are highly effective at inducing apoptosis in BCL-2/\(BCL-X_L\)-dependent cancers but are rendered inactive by overexpression of MCL-1, a formidable chemoresistance protein that lies outside the molecule's binding spectrum. By screening a library of stabilized alpha-helices of BCL-2 domains (SAHBs), we previously discovered that the MCL-1 BH3 helix is itself a potent and exclusive MCL-1 inhibitor. Here, we deployed this chemically-constrained peptidic inhibitor of MCL-1, MCL-1 SAHB, in a competitive binding screen to identify selective small molecule inhibitors of MCL-1. Rigorous in vitro binding and functional assays were used to validate the compounds and their mechanisms of action, and most notably, MCL-1 inhibitor molecule 1 (MIM1) displayed exquisite selectivity in these assays. NMR analysis documented that MIM1 engages the canonical BH3-binding pocket of MCL-1. Importantly, MIM1 selectively triggers caspase 3/7 activation and apoptosis of a cancer cell line that is dependent on induced overexpression of MCL-1 but showed no activity in the isogenic cell line that is driven instead by overexpressed \(BCL-X_L\). Thus, a selective stapled peptide inhibitor of MCL-1 was successfully applied to identify a high fidelity small molecule inhibitor of MCL-1 that exhibits anti-cancer activity in the specific context of MCL-1 dependence. |
en_US |
| dc.language.iso |
en_US |
en_US |
| dash.license |
LAA |
|
| dc.subject |
biology |
en_US |
| dc.subject |
cellular biology |
en_US |
| dc.title |
Selective Small Molecule Targeting of Anti-Apoptotic MCL-1 |
en_US |
| dc.type |
Thesis or Dissertation |
en_US |
| dc.date.available |
2012-11-14T13:40:53Z |
|
| thesis.degree.date |
2012 |
en_US |
| thesis.degree.discipline |
Biological Chemistry and Molecular Pharmacology |
en_US |
| thesis.degree.grantor |
Harvard University |
en_US |
| thesis.degree.level |
doctoral |
en_US |
| thesis.degree.name |
Ph.D. |
en_US |
| dc.contributor.committeeMember |
Eck, Michael |
en_US |
| dc.contributor.committeeMember |
Coen, Donald |
en_US |
| dc.contributor.committeeMember |
Danial, Nika |
en_US |
| dc.contributor.committeeMember |
Kritzer, Joshua |
en_US |
Files in this item
This item appears in the following Collection(s)
Show simple item record
Contact administrator regarding this item (to report mistakes or request changes)